<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab5">
 <label>Table 5</label>
 <caption>
  <p>Any grade AEs (≥10%) and corresponding Grade 3 or 4 AEs (Safety population)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th colspan="2">BTH1677/
     <break/>Bevacizumab/
     <break/>Carboplatin/Paclitaxel
     <break/>(
     <italic>N</italic> = 59)
    </th>
    <th colspan="2">Bevacizumab/
     <break/>Carboplatin/Paclitaxel
     <break/>(
     <italic>N</italic> = 30)
    </th>
   </tr>
   <tr>
    <th>Adverse events (AEs), n (%)</th>
    <th>All AEs</th>
    <th>Grade 3 or Grade 4 AEs</th>
    <th>All AEs</th>
    <th>Grade 3 or Grade 4 AEs</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Patients with at least 1 AE</td>
    <td>58 (98.3)</td>
    <td>55 (93.2)</td>
    <td>30 (100.0)</td>
    <td>20 (66.7)</td>
   </tr>
   <tr>
    <td colspan="5">Blood and lymphatic system disorders</td>
   </tr>
   <tr>
    <td> Neutropenia</td>
    <td>26 (44.1)</td>
    <td>23 (39.0)</td>
    <td>10 (33.3)</td>
    <td>8 (26.7)</td>
   </tr>
   <tr>
    <td> Thrombocytopenia</td>
    <td>20 (33.9)</td>
    <td>11 (18.6)</td>
    <td>10 (33.3)</td>
    <td>5 (16.7)</td>
   </tr>
   <tr>
    <td> Anemia</td>
    <td>14 (23.7)</td>
    <td>2 (3.4)</td>
    <td>8 (26.7)</td>
    <td>1 (3.3)</td>
   </tr>
   <tr>
    <td> Leukopenia</td>
    <td>9 (15.3)</td>
    <td>3 (5.1)</td>
    <td>2 (6.7)</td>
    <td>1 (3.3)</td>
   </tr>
   <tr>
    <td colspan="5">Gastrointestinal disorders</td>
   </tr>
   <tr>
    <td> Nausea</td>
    <td>40 (67.8)</td>
    <td>5 (8.5)</td>
    <td>16 (53.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Constipation</td>
    <td>25 (42.4)</td>
    <td>0</td>
    <td>9 (30.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Vomiting</td>
    <td>19 (32.2)</td>
    <td>2 (3.4)</td>
    <td>7 (23.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Diarrhea</td>
    <td>12 (20.3)</td>
    <td>2 (3.4)</td>
    <td>8 (26.7)</td>
    <td>1 (3.3)</td>
   </tr>
   <tr>
    <td> Abdominal pain upper</td>
    <td>6 (10.2)</td>
    <td>1 (1.7)</td>
    <td>1 (3.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Stomatitis</td>
    <td>6 (10.2)</td>
    <td>1 (1.7)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">General disorders and administration-site conditions</td>
   </tr>
   <tr>
    <td> Fatigue</td>
    <td>33 (55.9)</td>
    <td>1 (1.7)</td>
    <td>18 (60.0)</td>
    <td>1 (3.3)</td>
   </tr>
   <tr>
    <td> Pyrexia</td>
    <td>12 (20.3)</td>
    <td>2 (3.4)</td>
    <td>3 (10.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Chills</td>
    <td>11 (18.6)</td>
    <td>1 (1.7)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Mucosal inflammation</td>
    <td>6 (10.2)</td>
    <td>0</td>
    <td>3 (10.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Chest pain</td>
    <td>3 (5.1)</td>
    <td>0</td>
    <td>5 (16.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Infections and infestations</td>
   </tr>
   <tr>
    <td> Nasopharyngitis</td>
    <td>6 (10.2)</td>
    <td>0</td>
    <td>3 (10.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Urinary tract infection</td>
    <td>2 (3.4)</td>
    <td>1 (1.7)</td>
    <td>3 (10.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Injury, poisoning, and procedural complications</td>
   </tr>
   <tr>
    <td> Infusion-related reaction</td>
    <td>7 (11.9)</td>
    <td>1 (1.7)</td>
    <td>2 (6.7)</td>
    <td>1 (3.3)</td>
   </tr>
   <tr>
    <td colspan="5">Investigations</td>
   </tr>
   <tr>
    <td> Hemoglobin decreased</td>
    <td>4 (6.8)</td>
    <td>1 (1.7)</td>
    <td>3 (10.0)</td>
    <td>2 (6.7)</td>
   </tr>
   <tr>
    <td> Platelet count decreased</td>
    <td>3 (5.1)</td>
    <td>2 (3.4)</td>
    <td>3 (10.0)</td>
    <td>1 (3.3)</td>
   </tr>
   <tr>
    <td colspan="5">Metabolism and nutritional disorders</td>
   </tr>
   <tr>
    <td> Decreased appetite</td>
    <td>17 (28.8)</td>
    <td>1 (1.7)</td>
    <td>11 (36.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Hypokalemia</td>
    <td>6 (10.2)</td>
    <td>1 (1.7)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Musculoskeletal and connective tissue disorders</td>
   </tr>
   <tr>
    <td> Arthralgia</td>
    <td>19 (32.2)</td>
    <td>1 (1.7)</td>
    <td>6 (20.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Pain in extremity</td>
    <td>15 (25.4)</td>
    <td>0</td>
    <td>3 (10.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Back pain</td>
    <td>11 (18.6)</td>
    <td>1 (1.7)</td>
    <td>4 (13.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Myalgia</td>
    <td>12 (20.3)</td>
    <td>1 (1.7)</td>
    <td>2 (6.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Nervous system disorders</td>
   </tr>
   <tr>
    <td> Polyneuropathy</td>
    <td>16 (27.1)</td>
    <td>3 (5.1)</td>
    <td>6 (20.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Headache</td>
    <td>9 (15.3)</td>
    <td>1 (1.7)</td>
    <td>4 (13.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Neuropathy peripheral</td>
    <td>6 (10.2)</td>
    <td>0</td>
    <td>5 (16.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Dizziness</td>
    <td>7 (11.9)</td>
    <td>0</td>
    <td>3 (10.0)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Paresthesia</td>
    <td>7 (11.9)</td>
    <td>0</td>
    <td>2 (6.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Dysgeusia</td>
    <td>6 (10.2)</td>
    <td>0</td>
    <td>2 (6.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Psychiatric disorders</td>
   </tr>
   <tr>
    <td> Insomnia</td>
    <td>9 (15.3)</td>
    <td>0</td>
    <td>2 (6.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Sleep disorder</td>
    <td>5 (8.5)</td>
    <td>0</td>
    <td>4 (13.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Respiratory, thoracic and mediastinal disorders</td>
   </tr>
   <tr>
    <td> Dyspnea</td>
    <td>18 (30.5)</td>
    <td>3 (5.1)</td>
    <td>8 (26.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Cough</td>
    <td>18 (30.5)</td>
    <td>2 (3.4)</td>
    <td>7 (23.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Epistaxis</td>
    <td>14 (23.7)</td>
    <td>0</td>
    <td>10 (33.3)</td>
    <td>0</td>
   </tr>
   <tr>
    <td> Oropharyngeal pain</td>
    <td>8 (13.6)</td>
    <td>0</td>
    <td>2 (6.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Skin and subcutaneous tissue disorders</td>
   </tr>
   <tr>
    <td> Alopecia</td>
    <td>28 (47.5)</td>
    <td>2 (3.4)</td>
    <td>14 (46.7)</td>
    <td>0</td>
   </tr>
   <tr>
    <td colspan="5">Vascular disorders</td>
   </tr>
   <tr>
    <td> Hypertension</td>
    <td>14 (23.7)</td>
    <td>3 (5.1)</td>
    <td>7 (23.3)</td>
    <td>1 (3.3)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>Abbreviations: AE</italic> adverse events, 
   <italic>N</italic> overall sample size, 
   <italic>n</italic> number of patients
  </p>
 </table-wrap-foot>
</table-wrap>
